EGFR and non-small cell lung carcinoma: Similarly, other researchers demonstrated poorer treatment efficacy in the case of KRAS c.34G > T (p.G12C) and c.35G > T (p.G12V) mutations and found promising response rates in c.35G > A (p.G12D) and c.34G > A (p.G12S) KRAS-mutant NSCLC treated with EGFR-targeted TKIs [134].